Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.

Autor: Guo L; Beijing Hospital, Beijing, China., Xi Y; The Third Affiliated Hospital of Jinzhou Medical University, Liaoning, China., Li L; The First Affiliated Hospital of Ningbo University, Zhejiang, China., Guo K; Shiyan General Hospital of Dongfeng Motor, Hubei, China., Wu J; The Third Hospital of Wuhan, Hubei, China., Xu J; Eli Lilly and Company, Suzhou, China., Wang Y; Eli Lilly and Company, Suzhou, China., Wu G; Eli Lilly and Company, Suzhou, China., Si S; Eli Lilly and Company, Suzhou, China.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Jul; Vol. 26 (7), pp. 2979-2983. Date of Electronic Publication: 2024 Apr 10.
DOI: 10.1111/dom.15590
Databáze: MEDLINE